Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations

NCT03839342 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: Binimetinib
DRUG: Encorafenib

Sponsor

University Health Network, Toronto